Zobrazeno 1 - 3
of 3
pro vyhledávání: '"James T. Koerber"'
Autor:
Jason Ho, Christopher W. Davies, Hanine Rafidi, C. Andrew Boswell, Shang-Fan Yu, Lidia A. Nazarova, Sheila Ulufatu, James T. Koerber, Danielle Mandikian, Jeffrey Lau, Gregory Z. Ferl, Jack Sadowsky, James A. Ernst
Publikováno v:
Molecular cancer therapeutics. 19(4)
Full-length antibodies lack ideal pharmacokinetic properties for rapid targeted imaging, prompting the pursuit of smaller peptides and fragments. Nevertheless, studying the disposition properties of antibody-based imaging agents can provide critical
Autor:
Kelly M. Loyet, Neil N. Trivedi, Racquel Corpuz, Brian L. Yaspan, Tracy Staton, Henry R. Maun, Erin H. Christensen, Kathila R. Alatsis, Xiumin Wu, Michael T. Lipari, Yvonne Franke, Mark S. Dennis, Daniel Kirchhofer, Wyne P. Lee, Rahul Ahuja, Xiaocheng Chen, Ashley Morando, Diana Chang, James T. Koerber, Aija Kusi, Joseph R. Arron, John Liu, Guiquan Jia, Juan Zhang, Janet Jackman, Ping Wu, George H. Caughey, Yan Wu, Rajesh Vij, Luz D. Orozco, Lawrence B. Schwartz, Benjamin T. Walters, Charles Eigenbrot, Prescott G. Woodruff, Lawren C. Wu, David F. Choy, Robert A. Lazarus, Meire Bremer, Amy Dressen, Magda Babina, Tangsheng Yi, Savita Ubhayakar, Xiaorong Liang, Jeff Lutman, Siddharth Sukumaran, Jason A. Hackney, John V. Fahy, Julie Q. Hang, Cary D. Austin, Manda Wong
Publikováno v:
Cell, vol 179, iss 2
Cell
Cell
Severe asthma patients with low type 2 inflammation derive less clinical benefit from therapies targeting type 2 cytokines and have significant unmet medical needs. We show that mast cell tryptase is elevated in severe asthma patients, correlating wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8c0946c02d2066eb05676694e454e0e
https://escholarship.org/uc/item/8pf5p52n
https://escholarship.org/uc/item/8pf5p52n
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0197962 (2018)
PLoS ONE
PLoS ONE
Monoclonal antibodies (mAbs) have enabled numerous basic research discoveries and therapeutic approaches for many protein classes. However, there still exist a number of target classes, such as multi-pass membrane proteins, for which antibody discove